Conversely, overexpression of Djun (Jra, CG2275), the transcriptional effector of the JNK pathway, leads to reduction of the tumor burden (38% tumors, p = 0.0036, n = 40; 0% metastasis, p = 0.559; Figure 5F and 5I), partially mimicking overexpression of Ato expression. Here, MAPK8 is linked to neoplasm.